What to Watch When Twist Bioscience Reports Fiscal Q3 Results
Uncertainty is one of the central themes of investing in 2020, but investors can be certain of one thing: Valuing shares of Twist Bioscience (NASDAQ: TWST) at more than 30 times sales is a little bit ridiculous.
The company's technology platform is intriguing, but it hasn't shown signs of becoming a commercial success from a business standpoint. In fact, Twist Bioscience has reported growing losses as it has scaled its business and relied on equity financing to fund operations. That hasn't stopped the small-cap stock from soaring by more than 200% since the beginning of 2020.
On the one hand, Twist Bioscience is uniquely positioned to help customers respond to the coronavirus pandemic. It has also signed a flurry of drug discovery deals this year. On the other hand, the financial impacts of those catalysts are a bit fuzzy. Here's what metrics investors will be watching when the company reports fiscal third-quarter 2020 operating results.
Source Fool.com
